Maximizing the Global Impact of Monoclonal Antibodies for Children

About this Research Topic

Background

Monoclonal antibodies (mAbs) have revolutionized medicine, providing innovative treatments for many diseases. For decades, mAbs have increasingly become pivotal in paediatric care. Eculizumab has revolutionised atypical haemolytic uremic syndrome (HUS) treatment while palivizumab has significantly reduced hospitalizations from respiratory syncytial virus (RSV) in high-risk infants and children. The newly approved long-acting RSV mAbs nirsevimab and clesrovimab are now poised to extend and broaden this impact.

Despite their therapeutic efficacy, the widespread impact of mAbs, particularly in children has been hindered by barriers to global access. Using lower doses of mAbs for children (while essentially using the same formulations as adults) should reduce costs, pioneer greater access and lead to greater impact; however, infants and children remain neglected or suffer delays in access due to slow ethical approval, trial recruitment challenges and other issues. This is exemplified by the differential global availability of RSV mAbs and the lack of supply for many antitoxin antibody products for children such as for diphtheria where replacement mAbs offer an alternative, safer therapy yet investment remains insufficient.

Innovations in biotechnology are fostering efforts to make mAbs more accessible. Promising developments include reduced costs approaching vaccine-like pricing, non-inferiority of subcutaneous versus intravenous administration that may increase uptake in children (e.g., pembrolizumab data for childhood cancers) and a burgeoning, albeit early, pipeline of mAbs for the prevention and treatment of infectious diseases like malaria and HIV which particularly affect children. There have also been setbacks, such as with the revocation of EMA's and MHRA's approvals of crizanlizumab for sickle cell disease treatment amid limited clinical trial data from most-affected populations, such as in Africa.

This Frontiers in Pediatrics Research Topic aims to capture the currently unmet and future potential of mAbs on pediatric practice by analysing their past and present utilization, assessing their impact, and examining opportunities lost (or at risk) due to clinical development challenges, registration, and access limitations. The Research Topic strives to envision the potential uses of mAbs in child health and trace the ongoing R&D mAb development efforts dedicated to addressing childhood diseases, particularly those affecting underserved pediatric populations. Lastly, the Research Topic aims to explore how specific pathfinder pediatric mAbs could pave the way for enhanced global accessibility, demonstrating that low-dose, affordable mAbs can be broadly implemented, particularly in low- and middle-income countries.

To gather further insights into the role and pathway to impact of mAbs in pediatric global health, this Research Topic welcomes contributions that examine the topics outlined below. Contributions that explore pediatric mAbs in any context are welcome, although the series will aim to particularly focus on applications in low- and middle-income countries. The types of papers that will be considered include (but are not limited to):
• Innovations in lower-cost mAbs development and production, including costs of goods efficiencies, given low doses in children offer an initial route forward for LMIC access;
• Technological advancements in mAb formulations, routes of administration, presentation, supply chain, and delivery (including target product profile aspects to product design, such as the use of auto-disable syringes), with emphasis on resource-limited settings, and targeting pediatric use;
• Development of novel mAbs for infectious diease (e.g., gastrointestinal and respiratory) including for maternal administration with a view to protecting the foetus (e.g. Lassa fever or preventing mother to child transmission of HIV). Also non-communicable (e.g., childhood cancers, and haematology, rheumatology, and kidney diseases), and other (including rare) pediatric diseases, including the complementary role of mAbs with other modalities (including a review of the pediatric mAb pipeline);
• Opportunities (e.g., pediatric-informed PK/PD modelling) and challenges (patient recruitment) of accelerating regulatory approval and use of mAbs in children which are already approved for use in adults; and considerations to accelerate pediatric applications of mAb candidates currently in development for adult use;
• Implementation case studies, including market intelligence, financing models, and cost-effectiveness studies exploring enabling price thresholds to support broad access, as well as case studies illustrating global access challenges and opportunities to streamline mAb accessibility worldwide with a focus on pediatric indications;
• The role of various stakeholders (including funders and donors) in nurturing an environment that addresses upstream (research and development) and downstream structural challenges to the implementation of mAbs for pediatric use in low- and middle-income countries and having real impact with tangible products progressing through the pipeline and into implementation;
• Opportunities and efficiencies for vaccine-like pediatric mAb candidates stemming from the interplay between pediatric and/or maternal vaccines in development, complementary antibody correlates of protection research; and the role of mAbs given the increasing challenge of rising vaccine hesitancy;

This Research Topic is open to a broad range of article types, including systematic reviews, opinion articles, and original research (including clinical studies). Submissions on emerging mAbs, like long-acting RSV, HIV and malaria preventive therapies, more ambitious use of mAbs for pediatric unmet need (e.g. AMR and neonatal sepsis) and essential discussions on global access challenges and opportunities across pediatric applications are particularly encouraged.

Topic Editor Dr. Peter Gardner is currently Scientific Director in the global health team at LifeArc. LifeArc is a self-funded, not-for-profit life science organisation which collaborates,  funds, and carries out scientific research to ensure great science achieves its potential and reaches patients faster. This includes the discovery, development, and humanisation of monoclonal antibodies (mAbs) and providing R&D funding to tackle technical barriers to mAb affordability to increase global access and drive public health impact. Topic Editor Dr. Sébastien Morin works for the Medicines Patent Pool, a not-for-profit foundation that has prioritised several monoclonal antibodies (mAbs) for in-licensing as the first step towards working with biosimilar manufacturers to reduce the prices of such prioritised mAbs and increased their access for populations in low- and middle-income countries.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Classification
• Clinical Trial
• Editorial
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Classification
• Clinical Trial
• Editorial
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Study Protocol
• Systematic Review
• Technology and Code

Keywords: monoclonal antibodies, global health, medicines access, treatment, prevention, biologics, infectious disease, non-communicable disease, technology

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

• What is a Research Topic?

  Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

  Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

• Why does Frontiers publish Research Topics? 

  The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

  Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

• Why are Research Topics important for journals?

  As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

  A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

• How do we ensure the quality of articles within Research Topics?

  Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

  In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

• What are the benefits of publishing my article in a Research Topic?

  Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

  As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

  Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

   
• What types of articles can be published in a Research Topic?

  Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

  Check available article types here 

• Can I suggest a new Research Topic? 

  Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

  Suggest your topic here 

• Who leads a Research Topic? 

  A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

  The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

• What is the role of a topic editor?

  As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

   

  You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

• What support will I receive when editing a new Research Topic? 

  As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

• As a junior researcher, can I be involved in editing a Research Topic? 

  If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

• Can I get a certificate for editing a Research Topic?

  Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

• Who will I collaborate with?

  Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

• How long does it take to publish a Research Topic?

  As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

  Find out more about our Research Topics

• What fee support is available to authors publishing in a Research Topic?

  Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

  Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

• Will there be a printed version of my Research Topic?

  In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.